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Voltage-dependent anion channel 1Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase that is involved in the multiple
signaling processes of a cell. Increasing evidence suggests that GSK3β plays a key role in multiple cellular
processes in the progression of diabetes, obesity, Alzheimer's disease (AD), Parkinson's disease (PD), inﬂam-
matory diseases, schizophrenia, bipolar and several mood disorders, and mitochondrial diseases. Recent
research has found that increased GSK3β activity is linked to the pathogenesis of AD through amyloid beta
(Aβ), phosphorylated tau and mitochondrial dysfunction. Recent research has also revealed that GSK3β is
elevated in AD-affected tissues and is critically involved in dissociating the voltage-dependent anion channel
1 (VDAC1) protein from hexokinases, and causing disrupted glucose metabolism, mitochondrial dysfunction
and activating apoptotic cell death. The purpose of this article is to review recent research that is elucidating
the role of GSK3β in AD pathogenesis. We discuss the involvement of GSK3β in the phosphorylation of
VDAC1 and dissociation of VADC1 with hexokinases in AD neurons.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common mental illness, char-
acterized bydeﬁcits in cognition andmemory, aswell as changes in per-
sonality and behavior [1]. Currently, 5.4 million Americans suffer from
AD, and this number is expected to increase as elderly individuals live
longer [2]. Histopathological examination of postmortem brains from
AD patients revealed that extracellular amyloid beta (Aβ) plaques and
intracellular neuroﬁbrillary tangles (NFTs) are the major pathological
hallmarks of AD [3]. However, these pathological changes occur late in
the disease process, and they are unlikely to represent the primary
cause of clinical symptoms. Several other morphological and cellular
changes have been identiﬁed in the etiology of AD, including inﬂam-
matory responses, synaptic damage, defects in the cholinergic sys-
tem, abnormalities in the cell cycle, and mitochondrial structural
and functional abnormalities [4–12].
Recent research on glycogen synthase kinase 3 beta (GSK3β) re-
vealed that elevated GSK3β activity is directly linked to increased
levels of Aβ production and Aβ deposits, tau hyperphosphorylation,
and synaptic damage in AD patients and AD animal models [13–17].
It is possible that elevation of GSK3β activity in AD brains and braince, Oregon National Primate
ity, 505 NW 185th Avenue,
ax: +1 503 418 2701.
rights reserved.tissues from AD mouse models may occur due to Aβ association
with insulin, wnt signaling or NMDA receptors [18]. Based on reported
multiple cellular and pathological changes, several therapeutic strate-
gies have been used to test agents and drugs on experimental rodent
models, and on AD patients, including: Aβ-immunotherapy [19–21],
anti-inﬂammatory therapy [22–25], antioxidant therapy [26–36], cho-
linergic therapy [37–44], cell cycle therapy [45–47], hormonal therapy
[48–50], and inhibition of GSK3β activity [13–17] (Fig. 1). Although tre-
mendous progress has beenmade in understanding the AD progression
and pathogenesis, and in developing therapeutic strategies, we still not
have agents or drugs that can slow or prevent AD progression.
The purpose of this article is to review the latest developments of
GSK3β involvement in AD pathogenesis, particularly its association
with mitochondria in causing mitochondrial dysfunction and neuro-
nal damage. We also review and discuss GSK3β involvement in phos-
phorylation of VDAC1 and dissociating VADC1 with hexokinases in
AD neurons.
2. Mitochondrial dysfunction and Alzheimer's disease
Mitochondrial dysfunction is a prominent and early cellular change
in AD pathogenesis, but the precise mechanism underlying this
dysfunction is still not completely understood. Mitochondrial ab-
normalities and oxidative stress have been extensively described in
AD pathogenesis [2,11,12] (Fig. 2). Research on mitochondrial func-
tion revealed increased free radical production, lipid peroxidation,
Fig. 1. Therapeutic strategies in Alzheimer's disease. Based on these cellular and
pathological changes, multiple therapeutic strategies have been developed, including
Aβ-immunotherapy, anti-phosphorylated tau therapy, anti-inﬂammatory therapy, anti-
oxidant therapy, cholinergic therapy, cell cycle therapy, hormonal therapy, and inhibition
of GSK3β activity.
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damage, and reduced ATP production and cytochrome oxidase activ-
ity in postmortem AD-affected brain tissues [51–56]. Further, using
biochemical, molecular, gene expression, and electron microscopy
studies, and postmortem AD brains and brains from AβPP mice, sev-
eral studies found that Aβ is associated with mitochondrial dysfunc-
tion and neuronal damage [51,57–67]. Recent research also revealed
that phosphorylated tau is critically involved in defective axonal
transport of mitochondria, synaptic deprivation, oxidative stress,
and abnormal mitochondrial dynamics in AD pathogenesis [68,69].
A recent study reported that, in postmortem AD brains and brain
tissues from AβPP mice, Aβ (monomers and oligomers) and phos-
phorylated tau interacted with the mitochondrial outer membrane
protein VDAC1 [62], suggesting that Aβ and/or phosphorylated tau
may block the transport of organelles between mitochondria andFig. 2. Mitochondrial abnormalities in Alzheimer's disease pathogenesis. Multiple
mitochondrial abnormalities have been identiﬁed in Alzheimer's disease pathogenesis,
including abnormal mitochondrial gene expression, defective mitochondrial enzymatic
activities, accumulation of somatic mitochondrial DNA changes, abnormal mitochondrial
dynamics, impaired mitochondrial axonal transport, amyloid beta and amyloid precursor
protein associationwithmitochondria, and amyloid beta and phosphorylated tau interac-
tion with mitochondrial outer membrane protein, VDAC1. Research on mitochondrial
function revealed increased free radical production, lipid peroxidation, mitochondrial
ﬁssion-linked GTPase activity, oxidative DNA, and protein damage, and reduced ATP pro-
duction and cytochrome oxidase activity in postmortem Alzheimer's disease-affected
brain tissues and tissues from Alzheimer's disease mouse models and peripheral tissues
and cell models of Alzheimer's disease.the cytoplasm possibly causing defects in oxidative phosphorylation
andmitochondrial ATP synthesis. It is unclear howAβ and phosphor-
ylated tau each interact with VDAC1, and how these interactionsmay
lead to oxidative phosphorylation defects and the reduction of ATP
synthesis in neurons affected by AD.
3. VDAC1 and Alzheimer's disease
VDAC, which is ubiquitously located in the mitochondrial outer
membrane, is generally thought to be the primary means by which
metabolites diffuse in and out of mitochondria [70–72]. Three VDAC
isoforms (VDAC1, VDAC2, and VDAC3) have been found in mammalian
mitochondria. Of these isoforms, VDAC1 is the most widely expressed,
followed by VDAC2, and then VDAC3 [73,74]. The relevance of VDAC2
and VDAC3 is minimal for neurodegenerative diseases such as AD,
PD and HD because of their low expressions in neurons.
VDAC proteins perform several important functions in the cell,
including maintaining synaptic plasticity and mitochondrial perme-
ability transition (MPT) pore; and regulating the shape and structure
of mitochondria, hexokinase interactions with mitochondria, and ap-
optosis signaling [75,76]. The change in mitochondrial permeability
that is characteristic of apoptosis is mediated by the Bcl-2 family of
proteins, which binds to VDAC and alters channel kinetics and con-
ductance [75]. Recent research also revealed that VDAC is inhibited
by the cytoskeletal protein tubulin, resulting in impairments in channel
conductance [77]. In addition, several recent studies revealed that VDAC
proteins and their binding partners are modiﬁed post-translationally
due to VDAC phosphorylation and are involved in VDAC dysfunction
[78,79]. However, the causal factors of VDA1phosphorylation in AD
pathogenesis are not completely understood.
Di Pinto and colleagues [80] studied the role of alpha-helix of VDAC1
in pore activity. They synthesized the human VDAC1 N-terminal pep-
tide Ac-AVPPTYADLGKSARDVFTK-NH2 (Prn2-20) and determined its
structure by circular dichroism (CD) and nuclear magnetic resonance
spectroscopy. CD studies showed that the Prn2-20 peptide exists in an
aqueous solvent as an unstructured peptide without stable secondary
structure. No ordered structure was observed in dodecyl beta-maltoside.
Differential scanning calorimetric measurements were carried out in
order to examine the membrane afﬁnity of VDAC. Upon the interaction
with the negatively charged 1,2 dipalmitoyl-sn-glycero-3-phosphoserine
membrane, Prn2-20 exhibited distinctive behavior, suggesting that elec-
trostatics may play an important role. Interaction between the peptide
and artiﬁcial bilayers indicates that Prn2-20 lies on the membrane
surface. Recombinant HVDAC1 deletion mutants, devoid of N-terminal
amino acid 7 or 19, were used to transfect eukaryotic cells. In studies of
N-terminal VDAC structure, in which cells were transfected with human
VDAC1 lacking amino acid 7 or 19, the over-expression of human
VDAC1 increased the number of COS cells with depolarized mito-
chondria, which progressively reduced. The mitochondrial targeting
of the deletion mutants was unaffected. This study concluded that
the VDAC N-terminal peptide plays a role in the proper function of
VDAC1 during apoptotic events.
Geula and colleagues [81] studied the location and translocation of
the VDAC1 N-terminal domain, and its role in voltage-gating and as a
target for anti-apoptotic proteins. They used site-directed mutagenesis
and cysteine residue substitution, together with a thiol-speciﬁc cross-
linker, to determine whether the VDAC1 N-terminal region exists in a
dynamic equilibrium and is located fully within the pore or exposed
outside the β-barrel. Using a single cysteine-residue-bearing VDAC1,
they found that the N-terminal region lies within the pore. However,
the region can be exposed outside the β-barrel where it dimerizes
with the N-terminal domain of a second VDAC1 molecule. When the
N-terminal region α-helix structure was perturbed, intra-molecular
cross-linkingwas abolished and dimerizationwas enhanced. As a result
of this structural change, the mutant form of VDAC1 also displayed
reduced voltage-gating and reduced binding to hexokinase, but not to
Fig. 3. Human diseases that are associated with glycogen synthase kinase 3.
Fig. 4. Glycogen synthase kinase 3 beta and Alzheimer's disease pathology. Amyloid
beta-induced elevated GSK3β activity is a key event in abnormal APP processing,
increased Aβ production, and phosphorylation of tau and synaptic pathology in AD.
GSK3β is proposed to activate VDAC1 phosphorylation that ultimately leads to
mitochondrial dysfunction and synaptic damage in AD.
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in the N-terminal domain glycine-rich sequence yielded less intra-
molecular cross-linked product cut more dimerization, suggesting that
the glycine-rich sequence of VDAC1 provides the ﬂexibility needed for
N-terminal translocation from the internal pore to the channel face.
N-terminal mobilitymay thus contribute to channel gating and interac-
tion with anti-apoptotic proteins.
To determine the link between VDAC1 and AD, the Reddy research
team studied VDAC1 protein levels in cortical tissues from postmortem
AD brains at different stages of disease progression (early, deﬁnite,
and severe) and cortical tissues from 6-, 12-, and 24-month-old AβPP
mice. Progressively increased levels of VDAC1 protein were found in
the postmortem AD brains relative to the control subjects, and progres-
sively increased levels of VDAC1were also found in the cerebral cortices
of the 6-, 12-, and 24-month-old AβPP mice [62]. To determine the
physical interaction between VDAC1 and Aβ, we recently performed
co-IP analysis, using the VDAC1 antibody Aβ-6E10 and immunoblotting
analysis and protein lysates of cortical tissues from control subjects;
from patients with early, deﬁnite, and severe AD; and from APP,
APPxPS1, and 3XTg.AD mice. A 4 kDa Aβ was found in VDAC1-
IP-elutes from AD patients and from APP, APPxPS1, and 3XTg.AD
mice, indicating that Aβ interacts with VDAC1. Mitochondrial func-
tional parameters were found to be defective, including reduced
ATP and cytochrome oxidase activity, and levels of lipid peroxidation,
free radical production, and mitochondrial ﬁssion-linked GTPase ac-
tivity were elevated [62].
Thinnes (2011) [82] proposed that the GxxxG motif of the
N-terminal of VDAC1 might interact with the GxxxG motif of the
C-terminal of Aβ peptide in AD neurons. Thinnes proposed that the
GxxxG motifs are aggregation/membrane perturbation motifs and
that Aβ, a C-terminal cleaved product from APP by beta-secretase
BACE1 and gamma-secretase, may induce AD via apoptosis by opening
type-1 porin/VDAC in cell membranes of hypometabolic neuronal cells
[82]. Considering the ubiquitous expression nature of APP, beta- and
gamma-secretases and VDAC1, apoptosis might play a role in all these
proteins/motifs.
These research ﬁndings strongly support that the N-terminal
VDAC1 is critical for VDAC dimerization, and mitochondrial pore
gating activity. These ﬁndings also indicate that VDAC1 is elevated
in AD progression. It is possible that Aβ and phosphorylated tau are
strongly linked with N-terminal VDAC1 and may cause the blockage
of mitochondrial pores, which in turn may disrupt the transport
of proteins and metabolites between mitochondria and cytoplasm,
leading to defects in oxidative phosphorylation, mitochondrial dys-
function, and neuronal damage.
4. GSK3 structure and function
In 1980, GSK3was discovered as a regulatory kinase. It is encoded by
2 genes: GSK3α, located on chromosome 19, and GSK3β, located on
chromosome 2. GSK3 is ubiquitously expressed from yeast tomammals
and is recognized as a kinase for a large number of proteins involved in
multiple cellular pathways [83]. GSK3 is a serine/threonine protein
kinase that mediates the addition of phosphate molecules onto serine
and threonine amino acid residues.
GSK3α consists of a molecular mass of 51 kDa, and GSK3β, a molec-
ular mass of 47 kDa. These 2 isoforms are highly homologous at the
kinase domain, but are differentiated at the N- and C-terminal regions.
GSK3α contains an extended glycine-rich, N-terminal region that may
be responsible for cellular localization and interactions with other part-
ners [84]. The activities of GSK-3α and GSK-3 β are positively regulated
by the phosphorylation of Tyr279 and Tyr216, and negatively regulated
by the N-terminal phosphorylation of Ser21 and Ser9. Studies of GSK3β
knockout mice have revealed that the total absence of GSK3β is embry-
onically lethal, suggesting that GSK3αmay not compensate for the ab-
sence of GSK3β [85].Increasing evidence suggests that GSK3 dysregulation is implicated
in a large number of diseases, including AD [13,16,17,86], PD [87],
cancer [88–90], diabetes [91], inﬂammatory diseases [92], schizophrenia,
bipolar and severalmooddisorders [93], andmitochondrial diseases [94]
(Fig. 3). These diseases involve GSK3 activity in normal and disease
process. In addition, GSK3 is also involved in the regulation of several
cellular pathways, including cell migration [95], Wnt signaling [96],
phosphatidylinositol 3-kinase, and neurotrophic pathways in cell
survival [97]. Inactivation of GSK3 has been found to lead to cell
senescence [98]. Further, increased activation of GSK3β was found
to be pro-apoptotic, and its inhibition, anti-apoptotic [99–103].
Inhibition of GSK3β activity is suggested as a therapeutic strategy
for several neurodegenerative diseases, including AD and PD.
5. Production of GSK3β-mediated Aβ and phosphorylation of tau
In the recent years, several studies have focused on elucidating the
role of GSK3β in AD pathogenesis, mainly because of its known role in
causing the phosphorylation of tau and in producing increased levels
of Aβ and Aβ deposits in AD brains, AD mouse models, and AD ﬂy
models [13–17] (Fig. 4). They found that the inhibition of GSK3β
reduces AD pathology. Additional research using AD models found
ameliorated cognitive decline in ADmice [13,14]. Together, these re-
sults suggest that inactivation of GSK3βmay be useful as a therapeu-
tic strategy to AD patients.
Hurtado and colleagues [15] studied the roles of GSK3α and GSK3β
in AD pathogenesis, using novel viral and genetic approaches. They
developed recombinant adeno-associated virus 2/1 short hairpin RNA
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transgenic mice of Aβ plaques (PDAPP+/−), both Aβ plaques and NFTs
(PDAPP+/−; PS19+/−), or wild-type controls. They also found that the
knockdown of GSK3α, but not of GSK3β, resulted in the reduction of
senile plaques in PDAPP+/−, PS19+/−, and PDAPP+/− transgenic
mice. Moreover, they found that GSK3α and GSK3β knockdown in
combination, reduced the phosphorylation and misfolding of tau in
PS19+/− and PDAPP+/− mice.
To study the effects of GSK3α reduction on Aβ formation, Hurtado
et al. [15] generated triple transgenic mice using the CaMKIIα-Cre
(α-calcium/calmodulin-dependent protein kinase II-Cre) system
to knockdown GSK3α in PDAPP+/− mice. GSK3α KD signiﬁcantly
reduced Aβ and ameliorated memory deﬁcits in PDAPP+/− mice.
Their results suggest that GSK3α contributes to both SP and NFT
pathogenesis while GSK3β modulates NFT formation, suggesting
not only common but also different targets for both isoforms
[15].
In another study, Avrahami and colleagues [104] studied the ef-
fects of GSK3α and GSK3β in 5XFAD mice that co-express mutated
APP and PS1 and produce massive cerebral Aβ deposits. They found
that both GSK3α and GSK3β were hyperactive in this model. Nasal
treatment of 5XFAD mice with a novel substrate of competitive GSK3
inhibitor, L803-mts, reduced Aβ deposits and ameliorated cognitive
deﬁcits. Studies of 5XFAD brain samples indicated that L803-mts
restored the activity of mammalian targets of rapamycin and inhibited
autophagy. Lysosomal acidiﬁcation was impaired in the 5XFAD brains,
indicated by reduced cathepsin D activity and decreased N-glycoyslation
of the vacuolar ATPase subunit V0a1, a modiﬁcation required for ly-
sosomal acidiﬁcation. Treatment with L803-mts restored lysosomal
acidiﬁcation in 5XFAD brains. Studies in SH-SY5Y cells conﬁrmed
that GSK3α and GSK3β, in combination, impaired lysosomal acidiﬁ-
cation and that the treatment with L803-mts enhanced the acidic
lysosomal pool as demonstrated in LysoTracker Red-stained cells.
Further, L803-mts was found to restore the impairment of lysosomal
acidiﬁcation that was caused by dysfunctional PS1. These researchers
provide evidence that mTOR is a target activated by GSK3 but inhibited
by impaired lysosomal acidiﬁcation and elevation in amyloid precursor
protein/Aβ loads and inhibition of GSK3 restores lysosomal acidiﬁcation
that in turn enables clearance of Aβ burdens and reactivation of
mTOR [104].
Ly and colleagues [105] inhibited GSK3β to determine its protec-
tive effects. Using cell and molecular biology methods, they studied
AD pathology in cell culture and APP23 transgenic mice. They found
that the reduced GSK3β activity is involved in reducing BACE1-
mediated cleavage of APP and Aβ production by decreasing BACE1
gene transcription and expression. They also found that the regula-
tion of BACE1 gene expression by GSK3β was dependent on NF-κB
signaling. Inhibition of GSK3 signaling markedly reduced Aβ deposits
and NFTs, and rescued memory deﬁcits in the APP23 transgenic mice.
These data provide evidence that GSK β regulates BACE1 expression
and AD pathogenesis, and that the inhibition of GSK3 signaling
reduces Aβ neuropathology and alleviates memory deﬁcits in the
APP23 mice. These data suggest that interventions that speciﬁcally
target the β-isoform of GSK3 may be an effective approach for AD
patients.
DaRocha-Souto et al. [13] studied the role of oligomeric assem-
blies of Aβ in GSK3β activity using primary neuronal cultures and
APP/tau mice. They found an increased activity of GSK3β after expo-
sure to oligomeric Aβ in neurons in culture in the brain of double
transgenic APP/tau mice and in AD brains. Activation of GSK3β,
even in the absence of Aβ, is sufﬁcient to produce a phenocopy of
Aβ-induced dendritic spine loss in neurons in culture, while pharma-
cological inhibition of GSK3β prevents spine loss and increases ex-
pression of CREB-target genes like BDNF. Of note, in transgenic mice
GSK3β inhibition ameliorated plaque-related neuritic changes and in-
creased CREB-mediated gene expression. Moreover, GSK3β inhibitionrobustly decreased the oligomeric Aβ load in the mouse brain. All
these ﬁndings support the idea that GSK3β is aberrantly activated
by the presence of Aβ, and contributes, at least in part, to the neuro-
nal anatomical derangement associated with Aβ plaques in AD brains
and to Aβ pathology itself [13].
Leroy and colleagues [106] studied qualitative and quantitative
phosphorylation of tau by GSK3β using in vitro assays and NMR
spectroscopy. They found that three residues can be phosphorylated
(Ser-396, Ser-400, and Ser-404) by GSK3β alone, without priming.
Ser-404 is essential in this process, as its mutation to Ala prevents
all activity of GSK3β. However, priming enhances the catalytic efﬁca-
cy of the kinase, as initial phosphorylation of Ser-214 by the cAMP-
dependent protein kinase leads to the rapid modiﬁcation by GSK3β
of four regularly spaced additional sites. Because the regular incor-
poration of negative charges by GSK3β leads to a potential parallel
between phospho-tau and heparin, they investigated its interaction
with the heparin/low density lipoprotein receptor binding domain
of human apolipoprotein E. They observed an interaction between
the GSK3β-promoted regular phospho-pattern on tau and the apoli-
poprotein E fragment but none in the absence of phosphorylation or
the presence of an irregular phosphorylation pattern by the prolonged
activity of cAMP-dependent protein kinase. Apolipoprotein E is there-
fore able to discriminate and interact with speciﬁc phosphorylation
patterns of tau.
Using inducible gene expression system to express Arctic mu-
tant Aβ42 speciﬁcally in adult neurons in Drosophila model, Sofola
and colleagues [14] studied GSK3 mediated Aβ42 accumulation.
This ﬂy model was used to examine the role of events during adult-
hood and early AD etiology. Expression of Aβ42 in adult neurons
increased GSK3 activity, and inhibition of GSK3 (either genetically
or pharmacologically by lithium treatment) rescued Aβ42 toxicity.
Aβ42 pathogenesis was also reduced by removal of endogenous
ﬂy tau; but, within the limits of detection of available methods,
tau phosphorylation did not appear to be altered in ﬂies expressing
Aβ42. The GSK3-mediated effects on Aβ42 toxicity appear to be at
least in part mediated by tau-independent mechanisms, because
the protective effect of lithium alone was greater than that of the
removal of tau alone. Finally, Aβ42 levels were reduced upon
GSK3 inhibition, pointing to a direct role of GSK3 in the regulation
of Aβ42 peptide level, in the absence of APP processing. Their study
points to the need both to identify the mechanisms by which GSK3
modulates Aβ42 levels in the ﬂy and to determine if similar mech-
anisms are present in mammals, and it supports the potential ther-
apeutic use of GSK3 inhibitors in AD.
Overall, these studies indicate that both GSK3α and GSK3β are
involved in enhancing Aβ production and tau phosphorylation in
AD pathogenesis. However, it is unclear whether the exact mecha-
nism(s) of Aβ-induced GSK3α and GSK3β increased activities in AD.
Further, it is unclear whether Aβ production activates GSK3β activity
or vice versa in AD pathogenesis.6. AKT, PIK3, GSK3β, and Alzheimer's disease
The serine/threonine kinase (Akt), also known as protein kinase B,
has become a major focus of research because of its involvement in
several cellular processes, including cancer, insulin metabolism, and
AD [107]. The three isoforms of Akt – Akt1, Akt2, and Akt3 – are
reported to be involved in major intracellular signaling pathway
that is associated with apoptosis [108]. Akt is known to interact
with PIK3 to protect cells against several cellular insults, including
oxidative stress and apoptotic cell death. PI3K (or phosphatidylinositide
3-kinases) is a family of enzymes involved in several cellular functions,
including cell growth, proliferation, differentiation, motility, survival,
and intracellular trafﬁcking. Interestingly, PIK3 and Akt act negatively
with GSK3β and protect cells against GSK3β toxicity.
Fig. 5. A proposed model of amyloid beta-induced GSK3β and mitochondrial dysfunc-
tion in Alzheimer's disease. Increasing evidence suggests that in Alzheimer's disease
pathogenesis, elevated GSK3β activity is a key event in abnormal APP processing,
increased Aβ production, and hyperphosphorylation of tau. Amyloid beta-induced
GSK3β is associated with mitochondrial dysfunction via the phosphorylation of
VDAC1 and dissociation of hexokinases with VDAC1 in Alzheimer's disease. Elevated
GSK3β further activates abnormal APP processing, leading to increased Aβ production
and hyperphosphorylation of tau, like vicious cycle. Further, GSK3β phosphorylates
VDAC1 on threonine 51, resulting in the detachment of hexokinase from VDAC1 and
anti-apoptotic Bcl2 family of proteins. The detached hexokinase from mitochondria
may not be able to have access to mitochondrial ATP and may not able to supply
necessary ATP to glycolysis and glucose metabolism. Further, elevated GSK3β suppresses
Akt kinase, and reduced Akt kinase may not prevent apoptotic cell death in Alzheimer's
disease in neurons.
1917P.H. Reddy / Biochimica et Biophysica Acta 1832 (2013) 1913–1921As discussed above, GSK3β is highly expressed in the brain tis-
sue. It has been identiﬁed as an in vivo substrate of the Akt/PKB
pathway. Phosphorylation of the N-terminal serine 9 residue of
GSK3β by Akt/PKB is important for the inhibition of GSK3β during
insulin-dependent glycogen synthesis and neuronal survival. The
regulation of GSK3 by Akt is likely to affect other signaling events
where GSK3β is important such as the hyperphosphorylation of tau.
Several studies have reported that increased activity of Akt pro-
tects cells against toxic insults of oxidative stress, Aβ, and DNA dam-
age [109–111]. Several cell culture studies demonstrated that Akt and
PIK3, in combination, protect against Aβ toxicity [110,112].
Using cell and molecular biology methods, Ryder and Ni [113]
studied the Akt/PKB pathway in the kidney cells from AD patients
and postmortem brain cells from AD patients. They found that the
APP mutation and lymphoblast cells expressed the PS1 mutation.
They also found reduced levels of Akt/PKB, increased GSK3β activity
in AD neurons, and the colocalization of GSK3β and tau, suggesting
a possible interaction between Akt/GSK3β and tau in vivo in AD.
Tokutake et al. [114] developed a novel cell co-culture system to
assess the effects of physiologically relevant levels of extracellular
Aβ in donor cells on the phosphorylation of tau in recipient cells.
They demonstrated that physiologically relevant levels of secreted
Aβ are sufﬁcient to cause hyperphosphorylation of tau in recipient
N2a cells expressing human tau and in primary culture neurons.
Hyperphosphorylation of tau was inhibited by blocking Aβ produc-
tion in donor cells. The expression of familial AD-linked PSEN1
mutants and APP ΔE693 mutants that induce the production of oligo-
meric Aβ in donor cells results in a similar hyperphosphorylation of
tau in recipient cells. The mechanism underlying the Aβ-induced
tau hyperphosphorylation is mediated by the impaired insulin signal
transduction because we demonstrated that the phosphorylation of
Akt and GSK3β upon insulin stimulation is less activated under this
condition. Treating cells with the insulin-sensitizing drug rosiglitazone,
a peroxisome proliferator-activated receptor γ agonist, attenuates the
Aβ-dependent hyperphosphorylation of tau. These ﬁndings suggest
that the disturbed insulin signaling cascade may be implicated in the
pathways through which soluble Aβ induces tau phosphorylation.
Baki et al. [115] studied the role of presenilin-1 (PS1) in neuronal
PI3K/Akt signaling using primary neuronal cultures from wild-type
and PS1 null (PS1−/−) embryonic mouse brains. They found that
in PS1−/− cultures, the onset of neuronal maturation coincides with
a decrease in the PI3K-dependent phosphorylation–activation of
Akt and phosphorylation–inactivation of glycogen synthase kinase-3
(GSK-3). Mature PS1−/− neurons show increased activation of apo-
ptotic caspase-3 and progressive degeneration preceded by dendritic
retraction. Expression of exogenous WT PS1 or constitutively active
Akt in PS1−/− neurons stimulates PI3K signaling and suppresses
both caspase-3 activity and dendrite retraction. The survival effects
of PS1 are sensitive to inhibitors of PI3K kinase but insensitive to
gamma-secretase inhibitors. Familial AD mutations suppress the abil-
ity of PS1 to promote PI3K/AKT signaling, prevent phosphorylation/
inactivation of GSK3 and promote activation of caspase-3. These mu-
tation effects are reversed upon coexpression of constitutively active
Akt. These data indicate that the neuroprotective role of PS1 depends
on its ability to activate the PI3K/Akt signaling pathway and that PS1
FAD mutations increase GSK3 activity and promote neuronal apopto-
sis by inhibiting the function of PS1. These observations suggest that
stimulation of PI3K/Akt signaling may be beneﬁcial to FAD patients.
Overall, these studies suggest that familial ADmutationsmay suppress
the PI3K/Akt signaling pathway, which may in turn activate GSK3β
activity, resulting in neuronal damage in the neurons from AD patients.
7. GSK3β and its link with VDAC1 and hexokinases
GSK3β is associated with mitochondrial dysfunction via the phos-
phorylation of VDAC1 in AD patients. GSK3β hyperactivity has beenlinked to Aβ production, Aβ deposits, hyperphosphorylated tau, and
NFT formation [83,116]. GSK3β phosphorylates VDAC1 on threonine
51, resulting in the detachment of hexokinase from VDAC1 [117].
There are no published reports on VDAC2 and VDAC3 and their asso-
ciations with GSK3 phosphorylation, this may be because of low
levels of VDAC2 and VDAC3 expressions in the brain and other tissues
of mammals including rodents, humans and nonhuman primates.
Further research is needed to understand phosphorylation by GSK3β
of VDAC2 or VDAC3 in neurodegenerative diseases such as AD, PD and
HD and other mitochondrial diseases.
Pastorino et al. [117] reported that Akt mediates the binding of
hexokinase 2 to mitochondria by negatively regulating the activity
of GSK3β. On inhibition of Akt, GSK3β is activated and phosphorylates
VDAC. Hexokinase 2 is unable to bind to GSK3b-phosphorylated
VDAC1, resulting in the dissociation of hexokinase 2 from the
mitochondria. The inhibition of Akt potentiates chemotherapy-induced
cytotoxicity, an effect that is dependent onGSK3β activation and its abil-
ity to disrupt the binding of hexokinase 2 to mitochondria [117] (Fig. 5).
Given the capacity of GSK3β to phosphorylate VDAC1 in AD,
VDAC1 might be phosphorylated on the putative GSK3β epitope in
AD. It is possible that phosphorylated VDAC1 might result in the
inability of hexokinase to interact with VDAC1. Increasing evidence
also suggests that in AD pathogenesis, elevated GSK3β activity is
a key event in abnormal APP processing, increased Aβ production,
and hyperphosphorylation of tau [118,119]. However, the molecular
interactions among Aβ, GSK3β, and VDAC1, and among phosphory-
lated tau, GSK3β, and VDAC1 in AD progression are unclear. Research
is needed to understand molecular links among Aβ, phosphorylated
tau, GSK3β, andVDAC1 phosphorylation. Additional research is also
needed to elucidate how increased activity of GSK3β results in the
reduction of hexokinase and the subsequent detachment of hexoki-
nases from VDAC1 in AD neurons.
Hexokinase is a glycolytic enzyme that catalyzes the transfer of a
high-energy phosphate group to a hexose in the initial step in the
cellular utilization of free hexoses in a glycolytic pathway. Hexokinases
are expressed in various tissues, including the brain and liver, and
hexokinase 1 is highly expressed in the brain [120]. Hexokinase
1918 P.H. Reddy / Biochimica et Biophysica Acta 1832 (2013) 1913–1921consumes ATP in order to phosphorylate glucose in the glycolysis.
Several studies have shown that VDAC1 interacts not only with
hexokinase isoforms 1 and 2 but also with the Bcl2 family of proteins
[84,117,121–125]. Further, hexokinases 1 and 2 have been found to
bind to mitochondria via VDAC [84,117,121–125]. The binding of
hexokinase with VDAC allows the direct access of hexokinase to
mitochondrial ATP in the glycolytic pathway. Recent studies also
revealed that hexokinase inhibits apoptosis by binding to VDAC
and preventing the release of cytochrome c [84,122,125].
Several studies found increased VDAC1 in AD postmortem brains,
APP mice, and cells treated with Aβ [62,126,127], suggesting that this
elevation of VDAC1 may be because of Aβ-induction in AD process.
As discussed above, Aβ-induced GSK3β levels were found to be mark-
edly increased in AD brains, AD mouse models, and cells treated with
Aβ, and increased levels of Aβ-induced VDAC1 phosphorylation,
reduced hexokinase, and leading to reduced VDAC1–hexokinase in-
teraction. This reduced VDAC1–hexokinase interaction may in turn
lead to low ATP availability in mitochondria, resulting in reduced glu-
cose metabolism and uninhibited apoptosis in AD neurons. Based on
PET scan and functional MRI studies, increasing evidence suggests
the reduced glycolysis/glucose metabolism in the brains of AD pa-
tients [128–130]. It is possible that Aβ-induced elevated GSK3β activ-
ity progressively detaches hexokinases from VDACs in AD neurons,
leading to reduced glycolysis/glucose metabolism selectively in af-
fected regions in the brains of AD patients. However, further research
is needed to conﬁrm this notion.
Wang et al. [131] studied the neuroprotective effects of hesperidin,
a bioactive ﬂavonoid compound, on Aβ25–35-induced neurotoxicity
in PC12 cells. They found that the hesperidin signiﬁcantly inhibited
Aβ25–35-induced apoptosis by reversing Aβ-induced mitochondrial
dysfunction, including the mitochondrial permeability transition pore
opening, intracellular free calcium increase and reactive oxygen species
production. They also found reduced levels of hexokinase and increased
GSK3β in Aβ25–35 peptide treated cells. However, in the hesperidin-
pretreated cells, hexokinase levels were either normal or similar to
the hexokinase levels in untreated Aβ25–35 cells. They also found
that hesperidin activated Akt and inhibited GSK3β in cells pretreated
with Aβ25–35. Their observations suggest a mechanistic link between
GSK3β activation and mitochondrial damage in PC12 cells treated
with Aβ25–35 [128].
Using proteomic analysis, western blotting, and immunohistochem-
ical techniques, Cuadrado-Tejedor et al. [127] studied VDAC1 in AD
postmortem brains, APP mice, and Aβ cell cultures. They found that
VDAC1 was overexpressed in the hippocampus from AD transgenic
mice models and overexpressed in postmortem brain tissues from AD
patients at an advanced stage of AD. Interestingly, Aβ soluble oligomers
induced the upregulation of VDAC1 in a human neuroblastoma cell line,
supporting a correlation between Aβ levels and VDAC1 expression.
In hippocampal extracts from transgenic mice, a signiﬁcant increase in
VDAC1 was observed. The levels of hexokinase I, which interacts with
VDAC1 and affects its function, were decreased in mitochondrial sam-
ples from the APP mice. Elevated VDAC1 phosphorylation and reduced
mitochondrial hexokinase levelsmay facilitate the release of proapoptotic
factors, including bcl and bax, leading to defective function of VDAC
channel in AD neurons.
Overall, these studies suggest that an Aβ-induced increase in
GSK3β may be responsible for the inhibition of VDAC–hexokinase
interactions. The inhibited interaction between VDAC1 and hexoki-
nase may lead to low access of mitochondrial ATP to hexokinases in
the glycolytic pathway in AD neurons. The mechanistic link be-
tween Aβ-induced VDAC1 phosphorylation and impaired interac-
tion between VDAC1 and hexokinase in D neurons is not well
understood, and it is still not clear whether the activation of AKT
and/or the inhibition of GSK3β enhance hexokinase association
with VDAC1 in AD neurons. Additional research is needed to ad-
dress these issues.8. Conclusions and future studies
Mounting evidence suggests that mitochondrial dysfunction and
oxidative stress are involved in AD progression and pathogenesis.
Further, recent research on AD postmortem brains and brain tissues
from AβPP transgenic mice revealed that VDAC1 is increased in
AD-affected brain tissues from AβPP transgenic mice. Recent research
also revealed that VDAC1 interacts with Aβ and phosphorylated tau
and that these interactions progressively increased with disease pro-
gression. The abnormal VDAC1 interactionwith Aβ and phosphorylated
tau ultimately leads to the blockage ofMPTpores and a disruption in the
transport of proteins and metabolites between mitochondria and the
rest of the cell.
GSK3β activity was found to be elevated in AD postmortem brains
and AD transgenic mice. This increase in GSK3β activity has been
linked to Aβ production, Aβ deposits, hyperphosphorylated tau, and
NFT formation. GSK3β is associated with mitochondrial dysfunction
via VDAC1 phosphorylation in AD patients. GSK3β phosphorylates
VDAC1 on threonine 51, resulting in the detachment of hexokinase
from VDAC1. Recent research also revealed that Akt mediates the
binding of hexokinase 2 to the mitochondria by negatively regulating
the activity of GSK3β in the disease process.
To better understand themolecular bases amongAβ/phosphorylated
tau, VDAC1, GSK3β, and hexokinase in AD pathogenesis, the following
questions need to be addressed. (1) How do Aβ and phosphorylated
tau each interact with VDAC1, and do these interactions lead to oxida-
tive phosphorylation defects and the reduction of ATP synthesis in
neurons affected by AD? (2)What are the causal factors of VDAC1 phos-
phorylation in AD? (3) What is the mechanistic link between VDAC1
and Aβ, and what is the effect of the VDAC1–Aβ relationship on mito-
chondrial phenotypes, function, and neuronal damage? And (4) What
is the mechanistic link between Aβ-induced VDAC1 phosphorylation
and the consequent, impaired interaction between VDAC1 and hexoki-
nase in AD?
Addressing these questions will improve our basic understanding of
the AD process and may provide important information that can be
used in the development of therapeutic strategies to treat AD patients.
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